GERON CORP Net Cash Provided by (Used in) Investing Activities, Continuing Operations
GERON CORP (GERN) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $13.23 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-01.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-11-01
- GERON CORP net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $9.36M.
- GERON CORP net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $7.52M, a 15.22% decline year-over-year.
- GERON CORP net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $4.15M, a 27.50% decline year-over-year.
- GERON CORP net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was $792.00K, a 93.33% decline year-over-year.
- GERON CORP net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $8.76M, a 11902.74% increase from fiscal 2015.
- GERON CORP net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was $73.00K.
- GERON CORP net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$77.90M, a 470.02% decline from fiscal 2013.
- GERON CORP net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was $21.05M, a 65.46% decline from fiscal 2012.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-09-30 | $13.23M 10-Q · filed 2017-11-01 | |||
| 2017-03-31 | $9.36M 10-Q · filed 2017-05-09 | $16.88M derived: sum of 2 quarters · filed 2017-05-09 | $21.02M derived: sum of 3 quarters · filed 2017-11-01 | $21.81M derived: sum of 4 quarters · filed 2017-11-01 |
| 2016-12-31 | $7.52M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $11.66M derived: sum of 2 quarters · filed 2017-11-01 | $12.46M derived: sum of 3 quarters · filed 2017-11-01 | $8.76M 10-K · filed 2017-03-01 |
| 2016-09-30 | $4.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $4.94M derived: sum of 2 quarters · filed 2017-11-01 | $1.25M 10-Q · filed 2017-11-01 | $10.11M derived: sum of 4 quarters · filed 2017-11-01 |
| 2016-06-30 | $792.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | -$2.90M 10-Q · filed 2016-08-03 | $5.96M derived: sum of 3 quarters · filed 2017-05-09 | $11.68M derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-03-31 | -$3.69M 10-Q · filed 2017-05-09 | $5.17M derived: sum of 2 quarters · filed 2017-05-09 | $10.89M derived: sum of 3 quarters · filed 2017-05-09 | $22.77M derived: sum of 4 quarters · filed 2017-05-09 |
| 2015-12-31 | $8.87M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $14.59M derived: sum of 2 quarters · filed 2017-03-01 | $26.46M derived: sum of 3 quarters · filed 2017-03-01 | $73.00K 10-K · filed 2017-03-01 |
| 2015-09-30 | $5.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $17.59M derived: sum of 2 quarters · filed 2016-11-03 | -$8.79M 10-Q · filed 2016-11-03 | -$2.60M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $11.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | -$14.51M 10-Q · filed 2016-08-03 | -$8.32M derived: sum of 3 quarters · filed 2017-03-01 | -$5.88M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | -$26.39M 10-Q · filed 2016-05-05 | -$20.20M derived: sum of 2 quarters · filed 2017-03-01 | -$17.75M derived: sum of 3 quarters · filed 2017-03-01 | -$14.51M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $6.19M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $8.64M derived: sum of 2 quarters · filed 2017-03-01 | $11.88M derived: sum of 3 quarters · filed 2017-03-01 | -$77.90M 10-K · filed 2017-03-01 |
| 2014-09-30 | $2.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $5.69M derived: sum of 2 quarters · filed 2015-11-05 | -$84.09M 10-Q · filed 2015-11-05 | -$79.95M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-06-30 | $3.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$86.54M 10-Q · filed 2015-08-05 | -$82.40M derived: sum of 3 quarters · filed 2016-03-10 | -$76.35M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-03-31 | -$89.78M 10-Q · filed 2015-05-07 | -$85.64M derived: sum of 2 quarters · filed 2016-03-10 | -$79.59M derived: sum of 3 quarters · filed 2016-03-10 | -$78.39M derived: sum of 4 quarters · filed 2016-03-10 |
| 2013-12-31 | $4.14M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $10.19M derived: sum of 2 quarters · filed 2016-03-10 | $11.40M derived: sum of 3 quarters · filed 2016-03-10 | $21.05M 10-K · filed 2016-03-10 |
| 2013-09-30 | $6.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $7.26M derived: sum of 2 quarters · filed 2014-11-05 | $16.91M 10-Q · filed 2014-11-05 | $33.31M derived: sum of 4 quarters · filed 2015-03-11 |
| 2013-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $10.87M 10-Q · filed 2014-08-11 | $27.27M derived: sum of 3 quarters · filed 2015-03-11 | $43.53M derived: sum of 4 quarters · filed 2015-03-11 |
| 2013-03-31 | $9.66M 10-Q · filed 2014-05-01 | $26.06M derived: sum of 2 quarters · filed 2015-03-11 | $42.33M derived: sum of 3 quarters · filed 2015-03-11 | $51.10M derived: sum of 4 quarters · filed 2015-03-11 |
| 2012-12-31 | $16.40M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-11 | $32.67M derived: sum of 2 quarters · filed 2015-03-11 | $41.44M derived: sum of 3 quarters · filed 2015-03-11 | $60.95M 10-K · filed 2015-03-11 |
| 2012-09-30 | $16.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $25.04M derived: sum of 2 quarters · filed 2013-11-07 | $44.55M 10-Q · filed 2013-11-07 | $52.24M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-06-30 | $8.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $28.29M 10-Q · filed 2013-08-08 | $35.97M derived: sum of 3 quarters · filed 2014-03-17 | |
| 2012-03-31 | $19.51M 10-Q · filed 2013-05-03 | $27.20M derived: sum of 2 quarters · filed 2014-03-17 | ||
| 2011-12-31 | $7.69M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $32.14M 10-K · filed 2014-03-17 | ||
| 2011-09-30 | $24.45M 10-Q · filed 2012-11-02 | |||
| 2010-12-31 | -$48.45M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |